Today Anacor Pharmaceuticals (ANAC) Hits New Lifetime High

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Anacor Pharmaceuticals ( ANAC) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Anacor Pharmaceuticals as such a stock due to the following factors:

  • ANAC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $36.9 million.
  • ANAC has traded 5,429 shares today.
  • ANAC is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ANAC with the Ticky from Trade-Ideas. See the FREE profile for ANAC NOW at Trade-Ideas

More details on ANAC:

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. Currently there are 4 analysts that rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Anacor Pharmaceuticals has been 698,000 shares per day over the past 30 days. Anacor has a market cap of $2.9 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.72 and a short float of 9.9% with 7.10 days to cover. Shares are up 106.6% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Lack of Catalysts Keeps Analysts Away From Pfizer

Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp

Allergan's Dealmaking Continues With Vitae Takeout

Will Pfizer Book Another Healthy Quarter?

Ardelyx Has Big Potential

Ardelyx Has Big Potential